[Editorial] End of the road for daclizumab in multiple sclerosis

On March 7, the European Medicines Agency (EMA) recommended the immediate suspension and recall of the multiple sclerosis drug daclizumab. The announcement follows reports of serious inflammatory brain disorders in 12 patients worldwide, including three deaths, and comes shortly after the voluntary withdrawal of the drug by Biogen and AbbVie on March 2.
Source: LANCET - Category: General Medicine Authors: Tags: Editorial Source Type: research